Composition
Each scored film coated tablet contains:
Rosuvastatin (as calcium salt) .............................................................................
10 mg or 20 mg
Inactive ingredients:
Tablet core: Calcium phosphate dibasic anhydrous, lactose monohydrate, microcrystalline cellulose, magnesium stearate, crospovidone.

Tablet coat: Hydroxypropyl methylcellulose, talk purified, titanium dioxide, polyethylene glycol 4000, Carmoisine red.

Therapeutic Indications
Hyperlipidemia and Mixed Dyslipidemia:
Epirovastin is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia.
Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and nonpharmacological interventions alone has been inadequate.

Pediatric Patients 10 to 17 years of age with Heterozygous Familial Hypercholesterolemia (HeFH).
Adjunct to diet to reduce Total-C, LDL-C and ApoB levels in adolescent boys and girls, who are at least one year post-menarche, 10-17 years of age with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C > 190 mg/dL or > 160 mg/dL and there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors.

Hypertriglyceridemia:
Epirovastin is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia.

Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia):
Epirovastin is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia).

Homozygous Familial Hypercholesterolemia:
Epirovastin is indicated as adjunctive therapy to other lipid-lowering treatments (e.g.
LDL apheresis) or alone, if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia.

Slowing of the Progression of Atherosclerosis:
Epirovastin is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels.

Primary Prevention of Cardiovascular Disease:
In individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease based on age ≥ 50 years old in men and ≥ 60 years old in women, hsCRP ≥ 2 mg/L, and the presence of at least one additional cardiovascular disease risk factor such as hypertension, low HDL-C, smoking, or a family history of premature coronary heart disease, Epirovastin is indicated to:
reduce the risk of stroke,
reduce the risk of myocardial infarction, and
reduce the risk of arterial revascularization procedures.
Limitations of Use:
Epirovastin has not been studied in Fredrickson Type I and V dyslipidemias